Sign In
Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
AMGN.US
id: 619

Amgen ($AMGN) $74M Investor Settlement

The settlement terms have been submitted to the court for approval.
$74,000,000
Cash Settlement
S.D. New York
Court
1:23-CV-02138
Case number
07/29/2020
Class period Start
04/27/2022
Class period End
Amgen has agreed to a proposed $74 million settlement to resolve investor claims that it understated the size of IRS tax claims tied to its transfer pricing practices.

Outline:

On August 3, 2021, Amgen disclosed an IRS Notice of Deficiency seeking $3.6 billion in back taxes for 2010, 2011, and 2012. On April 27, 2022, it disclosed a second IRS notice seeking $5.1 billion for 2013, 2014, and 2015, plus a proposed $2 billion penalty. The case has now moved to a proposed $74 million settlement.

Timeline:
  • August 3, 2021: Amgen disclosed an IRS Notice of Deficiency seeking $3.6 billion in back taxes plus interest for 2010, 2011, and 2012.
  • April 27, 2022: Amgen disclosed a second IRS Notice of Deficiency seeking $5.1 billion in back taxes plus interest for 2013, 2014, and 2015, along with a proposed $2 billion penalty.
  • March 13, 2023: The initial lawsuit was filed in federal court.
  • April 19, 2026: The parties participated in mediation before David Murphy.
  • July 20, 2026: The parties reached an agreement-in-principle to settle for $74 million.
Background:

Amgen faced tax scrutiny over transfer pricing practices tied to earlier tax years. Investors say the company did not give the market a full picture of how large the IRS claims had become.

That issue first came into focus in August 2021, when Amgen disclosed an IRS Notice of Deficiency seeking $3.6 billion in back taxes plus interest for 2010 through 2012. The disclosure raised the stakes around the company’s tax position and its prior statements to investors.

The pressure grew further in April 2022. Amgen then disclosed a second IRS Notice of Deficiency seeking $5.1 billion in back taxes plus interest for 2013 through 2015, along with a proposed $2 billion penalty.

Investors say those disclosures showed that Amgen’s tax exposure was more serious than the market had understood. The case has now moved to a proposed $74 million settlement.

What Can Investors Expect Now?

Amgen has agreed to a proposed $74 million settlement to resolve investor claims that it understated the size of IRS tax claims tied to its transfer pricing practices.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.
Case Type
US Securities Class Action
Case Status
Stipulative Settlement
Alleged Offence
Mismanagement
Misleading Statements
Financial Misrepresentation
Fraud
Failure to Disclose
Malpractice
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Service Provider
Security Type
Stocks
Trade Direction
Long
Payout per Share
1.66
Filing date
03/13/2023
Lead Plaintiff Deadline
05/12/2023
Plaintiffs
Roofers Local No. 149 Pension Fund
Attorneys
AsherKelly (Southfield, MI) Robbins Geller Rudman & Dowd LLP (Melville, NY)
Administrator
Verita Global
Attorney fee
$25,166,420
Trades matching type
FIFO

Frequently Asked Questions

How Do Class Action Settlements Work and How Can Investors Get Paid?

How Can Financial Institutions Recover Settlement Funds with 11th.com?

Why Do Investors Trust 11th.com?

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.